vs
Apellis Pharmaceuticals, Inc.（APLS）与NEOGENOMICS INC（NEO）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是NEOGENOMICS INC的1.1倍（$199.9M vs $186.7M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -57.9%，领先28.4%），NEOGENOMICS INC同比增速更快（11.1% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.5%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
APLS vs NEO — 直观对比
营收规模更大
APLS
是对方的1.1倍
$186.7M
营收增速更快
NEO
高出17.0%
-5.9%
净利率更高
APLS
高出28.4%
-57.9%
两年增速更快
APLS
近两年复合增速
6.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $186.7M |
| 净利润 | $-59.0M | $-108.0M |
| 毛利率 | — | 43.3% |
| 营业利润率 | -25.6% | 46.9% |
| 净利率 | -29.5% | -57.9% |
| 营收同比 | -5.9% | 11.1% |
| 净利润同比 | -62.2% | 42.0% |
| 每股收益（稀释后） | $-0.40 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSNEO
| Q1 26 | — | $186.7M | ||
| Q4 25 | $199.9M | $190.2M | ||
| Q3 25 | $458.6M | $187.8M | ||
| Q2 25 | $178.5M | $181.3M | ||
| Q1 25 | $166.8M | $168.0M | ||
| Q4 24 | $212.5M | $172.0M | ||
| Q3 24 | $196.8M | $167.8M | ||
| Q2 24 | $199.7M | $164.5M |
净利润APLSNEO
| Q1 26 | — | $-108.0M | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-27.1M | ||
| Q2 25 | $-42.2M | $-45.1M | ||
| Q1 25 | $-92.2M | $-25.9M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $-17.7M | ||
| Q2 24 | $-37.7M | $-18.6M |
毛利率APLSNEO
| Q1 26 | — | 43.3% | ||
| Q4 25 | — | 43.8% | ||
| Q3 25 | — | 42.8% | ||
| Q2 25 | — | 42.6% | ||
| Q1 25 | — | 43.6% | ||
| Q4 24 | — | 44.9% | ||
| Q3 24 | — | 44.6% | ||
| Q2 24 | — | 44.1% |
营业利润率APLSNEO
| Q1 26 | — | 46.9% | ||
| Q4 25 | -25.6% | -7.1% | ||
| Q3 25 | 48.7% | -14.4% | ||
| Q2 25 | -18.6% | -26.3% | ||
| Q1 25 | -50.0% | -16.6% | ||
| Q4 24 | -12.3% | -10.7% | ||
| Q3 24 | -24.0% | -12.6% | ||
| Q2 24 | -14.7% | -13.3% |
净利率APLSNEO
| Q1 26 | — | -57.9% | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -14.4% | ||
| Q2 25 | -23.6% | -24.9% | ||
| Q1 25 | -55.3% | -15.4% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | -10.5% | ||
| Q2 24 | -18.9% | -11.3% |
每股收益（稀释后）APLSNEO
| Q1 26 | — | $-0.13 | ||
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $146.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $828.8M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSNEO
| Q1 26 | — | $146.1M | ||
| Q4 25 | $466.2M | $159.6M | ||
| Q3 25 | $479.2M | $164.1M | ||
| Q2 25 | $370.0M | $154.7M | ||
| Q1 25 | $358.4M | $346.2M | ||
| Q4 24 | $411.3M | $367.0M | ||
| Q3 24 | $396.9M | $362.0M | ||
| Q2 24 | $360.1M | $355.1M |
总债务APLSNEO
| Q1 26 | — | — | ||
| Q4 25 | — | $341.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $541.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益APLSNEO
| Q1 26 | — | $828.8M | ||
| Q4 25 | $370.1M | $836.6M | ||
| Q3 25 | $401.2M | $838.3M | ||
| Q2 25 | $156.3M | $854.0M | ||
| Q1 25 | $164.2M | $888.3M | ||
| Q4 24 | $228.5M | $902.3M | ||
| Q3 24 | $237.1M | $908.2M | ||
| Q2 24 | $264.3M | $915.9M |
总资产APLSNEO
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $821.4M | $1.4B | ||
| Q1 25 | $807.3M | $1.6B | ||
| Q4 24 | $885.1M | $1.6B | ||
| Q3 24 | $901.9M | $1.6B | ||
| Q2 24 | $904.5M | $1.6B |
负债/权益比APLSNEO
| Q1 26 | — | — | ||
| Q4 25 | — | 0.41× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-8.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSNEO
| Q1 26 | — | $-8.1M | ||
| Q4 25 | $-14.2M | $1.3M | ||
| Q3 25 | $108.5M | $8.9M | ||
| Q2 25 | $4.4M | $20.3M | ||
| Q1 25 | $-53.4M | $-25.3M | ||
| Q4 24 | $19.4M | $9.8M | ||
| Q3 24 | $34.1M | $9.2M | ||
| Q2 24 | $-8.3M | $13.9M |
自由现金流APLSNEO
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $-6.5M | ||
| Q3 25 | $108.3M | $570.0K | ||
| Q2 25 | $4.4M | $14.0M | ||
| Q1 25 | $-53.4M | $-29.8M | ||
| Q4 24 | $19.3M | $-1.8M | ||
| Q3 24 | — | $-1.6M | ||
| Q2 24 | $-8.4M | $814.0K |
自由现金流率APLSNEO
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | -3.4% | ||
| Q3 25 | 23.6% | 0.3% | ||
| Q2 25 | 2.5% | 7.7% | ||
| Q1 25 | -32.0% | -17.8% | ||
| Q4 24 | 9.1% | -1.0% | ||
| Q3 24 | — | -0.9% | ||
| Q2 24 | -4.2% | 0.5% |
资本支出强度APLSNEO
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.1% | ||
| Q3 25 | 0.0% | 4.4% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.0% | 2.7% | ||
| Q4 24 | 0.0% | 6.7% | ||
| Q3 24 | 0.0% | 6.4% | ||
| Q2 24 | 0.0% | 8.0% |
现金转化率APLSNEO
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NEO
暂无分部数据
